CClinicalTrials.gg
RecruitingNCT06170645PAF-tVNSUpdated May 6, 2026

Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue

An interventional study of APA program and Active transcutaneous VNS in Chronic Fatigue Syndrome, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Chronic fatigue is enhanced by adapted physical activity (APA) programs. Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid benefit from a 4-6 week APA program, with 2 sessions per week. While most patients are improved by these exercise-training programs, for some the benefits remain very modest, and patients describe persistent fatigue. The literature unanimously describes the necessity of longer APA protocols (8-12 weeks, 2-3 sessions/week) for fatigue reduction in fibromyalgia and long Covid. However, it seems difficult to adhere to an optimal program as described in the literature for these fatigued patients. The investigators want to test a device that would both reduce fatigue and improve recovery between APA sessions, in order to gradually reach the recommendations for APA practice. Transcutaneous vagal nerve stimulation (tVNS) seems to be a promising approach. Thus, combining an APA intervention with a tVNS protocol could potentiate the expected and now well-known effect of exercise.

02

Conditions studied

  • Chronic Fatigue Syndrome

Keywords

  • Chronic fatigue
  • Transcutaneous vagal nerve stimulation (tVNS)
  • adapted physical activity (APA)
03

In context

Fatigue Syndrome, Chronic

246 studies on the registry are indexed under Fatigue Syndrome, Chronic; 58 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 166 interventional studies indexed under Fatigue Syndrome, Chronic.

Browse Fatigue Syndrome, Chronic studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 578 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient over 18 years old
  • Signature of informed consent
  • Confirmed diagnosis of fibromyalgia or long Covid (ACR 2016 criteria and persistent symptoms lasting more than 6 months after a positive RT-PCR test, respectively)
  • Persistent fatigue after an exercise rehabilitation program (FSS score > 36)
  • Physical inactivity, i.e. \<150 minutes per week of physical activity

Exclusion criteria

Exclusion Criteria:

  • Pre-existing atrial fibrillation,
  • Left ventricular ejection fraction \<40%
  • Severe heart failure
  • Recent stroke or myocardial infarction (\<6 months)
  • Unilateral or bilateral vagotomy
  • Pregnancy or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Patients with active tVNS

    Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.

    Other: APA program · Other: Active transcutaneous VNS

  • Sham comparator
    Patients with sham tVNS

    Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.

    Other: APA program · Other: Sham transcutaneous VNS

Interventions

  • OtherAPA program

    An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.

  • OtherActive transcutaneous VNS

    After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.

  • OtherSham transcutaneous VNS

    After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.

06

What researchers measure

Primary outcomes

  1. Fatigue evaluation assessed by autonomic nervous system activity

    The root mean square of successive differences in heart rate (in milliseconds) will be measured from a nocturnal Holter ECG recording (Novacor, Paris, France) at the end of the 3-month APA and tVNS programme (month 3) and compared with pre-programme values (inclusion).

    Time frame: Month : 0; 3

Secondary outcomes

  1. Fatigue Severity Scale (FSS)

    Subjective fatigue assessed by FSS, score from 9 to 63. The higher the score, the more severe the fatigue is and the more it affects the person's activities.

    Time frame: Month : 0; 6

  2. Medical Outcome Study Short Form questionnaire (MOS-SF 12)

    Quality of life assessed by the MOS-SF 12 questionnaire , score from 0 to 100. A low score reflects a perception of poor health, loss of function and the presence of pain. A high score reflects a perception of good health, absence of functional deficit and pain.

    Time frame: Month : 0; 6

  3. Pittsburgh questionnaire

    Quality of sleep assessed by Pittsburgh questionnaire (score 0 to 21). The 7 components of the score add up to give an overall score ranging from give an overall score ranging from 0 to 21 points, with 0 meaning that there are no difficulties, and 21 indicating major difficulties.

    Time frame: Month : 0; 6

  4. 6-minute walk test (6MWT)

    Physical condition assessed by the walking distance covered in the 6MWT, walking distance in m.

    Time frame: Month : 0; 6

  5. Adult Physical Activity Questionnaire (APAQ)

    Physical activity assessed by the APAQ, time spend to physical activity in hours/day.

    Time frame: Month : 0; 6

  6. Step count per day

    Objective physical activity assessed by step count per day using a Garmin Vivofit 4 activity tracker.

    Time frame: Month : 0; 6

  7. Ratio of Low Frequency to High Frequency (LF/HF)

    The autonomic balance (sympathetic/parasympathetic) will be analysed by measuring the LF/HF ratio on the basis of a nocturnal Holter ECG recording (Novacor, Paris, France).

    Time frame: Month : 0; 6

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier de Saint-Etienne
    Saint-Etienne, 42055, France
    • David HUPIN, MD · Contact
    • Frédéric ROCHE, MD PhD · Contact
    • David HUPIN, MD · Principal investigator
    • Léonard FEASSON, MD PhD · Sub investigator
    • Frédéric ROCHE, MD PhD · Sub investigator
    • Philippe BOIRON, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06170645
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Oct 3, 2024
Primary completion
Feb 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
May 6, 2026

Study contacts

David HUPIN, MD
Contact
david.hupin@chu-st-etienne.fr
(0)4 77 82 84 13 ext. +33
Hélène RAINGARD, CRA
Contact
helene.raingard@chu-st-etienne.fr
(0)4 77 12 08 26 ext. +33
David HUPIN, MD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion